{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:31:55Z","timestamp":1793475115388,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The University of Osaka","id":[{"id":"https:\/\/ror.org\/035t8zc32","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Phase III trials have established the efficacy of immune-based therapies for unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC). However, real-world evidence comparing regimens and clinically applicable prognostic biomarkers remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated 245 patients with unresectable advanced\/recurrent ESCC treated with first-line 5-fluorouracil plus cisplatin combined with nivolumab or pembrolizumab (CF\u2009+\u2009ICI; n\u2009=\u2009114), first-line ipilimumab plus nivolumab (Ipi\u2009+\u2009Nivo; n\u2009=\u200946), or nivolumab monotherapy as second-line or later treatment (Nivo; n\u2009=\u200985). Efficacy, safety, and survival outcomes were assessed, focusing on inflammation-based nutritional indices and multivariate prognostic modelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The objective response rates were 56%, 53%, and 27%, and the median overall survival was 26, 73, and 13\u00a0months in the CF\u2009+\u2009ICI, Ipi\u2009+\u2009Nivo, and Nivo groups, respectively. No treatment-related deaths occurred. In multivariate analyses, Glasgow Prognostic Score (GPS)\u2009\u2265\u20092 independently predicted poor survival across all regimens. High platelet-to-lymphocyte ratio (PLR) was independently associated with poor survival only in chemotherapy-free ICI regimens (Ipi\u2009+\u2009Nivo and Nivo). A pooled model showed a significant interaction between treatment regimen and PLR (p\u2009=\u20090.047).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In real-world practice, GPS provides regimen-independent prognostic stratification, whereas PLR shows treatment-dependent prognostic relevance, supporting its potential utility for biomarker-guided and individualized treatment selection in ESCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10388-026-01243-x","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:11:14Z","timestamp":1787893874000},"page":"869-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment-dependent and independent prognostic value of inflammation-based nutritional indices in immune checkpoint inhibitor-based therapy for esophageal cancer"],"prefix":"10.1007","volume":"23","author":[{"given":"Hiroki","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-4217","authenticated-orcid":false,"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeto","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaomi","family":"Hagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Momose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Motoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"issue":"3","key":"1243_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1243_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","volume":"154","author":"CC Abnet","year":"2018","unstructured":"Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360\u201373. https:\/\/doi.org\/10.1053\/j.gastro.2017.08.023.","journal-title":"Gastroenterology"},{"key":"1243_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-025-01176-x","author":"T Makino","year":"2025","unstructured":"Makino T, Nakai S, Hagi T, Momose K, Yamashita K, Saito T, et al. Conversion surgery following immunochemotherapy for initially unresectable\/recurrent esophageal cancer. Esophagus. 2025. https:\/\/doi.org\/10.1007\/s10388-025-01176-x.","journal-title":"Esophagus"},{"issue":"3","key":"1243_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10388-024-01056-w","volume":"21","author":"T Makino","year":"2024","unstructured":"Makino T, Nakai S, Momose K, Yamashita K, Tanaka K, Miyata H, et al. Efficacy and survival of nivolumab treatment for recurrent\/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort. Esophagus. 2024;21(3):319\u201327. https:\/\/doi.org\/10.1007\/s10388-024-01056-w.","journal-title":"Esophagus"},{"issue":"3","key":"1243_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.surg.2023.05.040","volume":"174","author":"R Teranishi","year":"2023","unstructured":"Teranishi R, Makino T, Tanaka K, Yamashita K, Saito T, Yamamoto K, et al. Long-term survival and prognostic factors associated with curative conversion surgery for ct4b esophageal squamous cell carcinoma: analysis of 200 consecutive cases. Surgery. 2023;174(3):558\u201366. https:\/\/doi.org\/10.1016\/j.surg.2023.05.040.","journal-title":"Surgery"},{"issue":"4","key":"1243_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jtcvs.2025.01.017","volume":"170","author":"T Makino","year":"2025","unstructured":"Makino T, Yamasaki M, Nakai S, Momose K, Yamashita K, Tanaka K, et al. Surgical and long-term outcomes of combined organ resection for esophageal cancer invading adjacent organs: experience of 90 consecutive cases. J Thorac Cardiovasc Surg. 2025;170(4):957\u201368. https:\/\/doi.org\/10.1016\/j.jtcvs.2025.01.017.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"6","key":"1243_CR7","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1002\/ags3.70036","volume":"9","author":"T Sugase","year":"2025","unstructured":"Sugase T, Miyata H, Kanemura T, Matsuura N, Makino T, Yamasaki M, et al. Long-term survival of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced esophageal cancer: a multicenter randomized phase II trial. Ann Gastroenterol Surg. 2025;9(6):1144\u201354. https:\/\/doi.org\/10.1002\/ags3.70036.","journal-title":"Ann Gastroenterol Surg"},{"issue":"9","key":"1243_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang C, Thudium KB, Han M, Wang XT, Huang H, Feingersh D, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846\u201356. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0040.","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"1243_CR9","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167\u201375. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1243_CR10","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(19)30626-6.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1243_CR11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10388-022-00920-x","volume":"19","author":"T Kojima","year":"2022","unstructured":"Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, et al. First-line pembrolizumab + chemotherapy in Japanese patients with advanced\/metastatic esophageal cancer from KEYNOTE-590. Esophagus. 2022;19(4):683\u201392. https:\/\/doi.org\/10.1007\/s10388-022-00920-x.","journal-title":"Esophagus"},{"issue":"5","key":"1243_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2111380.","journal-title":"N Engl J Med"},{"issue":"5","key":"1243_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00108-0.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1243_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s10388-025-01120-z","volume":"22","author":"S Nakai","year":"2025","unstructured":"Nakai S, Makino T, Momose K, Yamashita K, Tanaka K, Miyata H, et al. Exploring predictive biomarkers of efficacy and survival with nivolumab treatment for unresectable\/recurrent esophageal squamous cell carcinoma. Esophagus. 2025;22(3):360\u201372. https:\/\/doi.org\/10.1007\/s10388-025-01120-z.","journal-title":"Esophagus"},{"issue":"12","key":"1243_CR15","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41416-023-02235-9","volume":"128","author":"Y Hayashi","year":"2023","unstructured":"Hayashi Y, Makino T, Sato E, Ohshima K, Nogi Y, Kanemura T, et al. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br J Cancer. 2023;128(12):2175\u201385. https:\/\/doi.org\/10.1038\/s41416-023-02235-9.","journal-title":"Br J Cancer"},{"key":"1243_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408700","volume":"15","author":"S Tan","year":"2024","unstructured":"Tan S, Zheng Q, Zhang W, Zhou M, Xia C, Feng W. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review. Front Immunol. 2024;15:1408700. https:\/\/doi.org\/10.3389\/fimmu.2024.1408700.","journal-title":"Front Immunol"},{"issue":"1","key":"1243_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-022-00571-5","volume":"13","author":"M Gou","year":"2022","unstructured":"Gou M, Zhang Y. Pretreatment platelet-to-lymphocyte ratio (PLR) as a prognosticating indicator for gastric cancer patients receiving immunotherapy. Discov Oncol. 2022;13(1):118. https:\/\/doi.org\/10.1007\/s12672-022-00571-5.","journal-title":"Discov Oncol"},{"issue":"6","key":"1243_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/ags3.70057","volume":"9","author":"M Yamamoto","year":"2025","unstructured":"Yamamoto M, Omori T, Masuike Y, Shinno N, Hara H, Sugase T, et al. Postoperative prognostic nutritional index as a useful prognostic factor in patients with gastric cancer. Ann Gastroenterol Surg. 2025;9(6):1181\u201390. https:\/\/doi.org\/10.1002\/ags3.70057.","journal-title":"Ann Gastroenterol Surg"},{"issue":"6","key":"1243_CR19","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/SLA.0000000000003445","volume":"273","author":"S Urakawa","year":"2021","unstructured":"Urakawa S, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, et al. Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in metastatic esophageal cancer. Ann Surg. 2021;273(6):1141\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000003445.","journal-title":"Ann Surg"},{"issue":"5","key":"1243_CR20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/SLA.0000000000003129","volume":"271","author":"T Hashimoto","year":"2020","unstructured":"Hashimoto T, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, et al. The pattern of residual tumor after neoadjuvant chemotherapy for locally advanced esophageal cancer and its clinical significance. Ann Surg. 2020;271(5):875\u201384. https:\/\/doi.org\/10.1097\/SLA.0000000000003129.","journal-title":"Ann Surg"},{"issue":"3","key":"1243_CR21","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1097\/SLA.0000000000005104","volume":"277","author":"T Noma","year":"2023","unstructured":"Noma T, Makino T, Ohshima K, Sugimura K, Miyata H, Honma K, et al. Immunoscore signatures in surgical specimens and tumor-infiltrating lymphocytes in pretreatment biopsy predict treatment efficacy and survival in esophageal cancer. Ann Surg. 2023;277(3):e528\u201337. https:\/\/doi.org\/10.1097\/SLA.0000000000005104.","journal-title":"Ann Surg"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-026-01243-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-026-01243-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-026-01243-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:17:12Z","timestamp":1793474232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-026-01243-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1243"],"URL":"https:\/\/doi.org\/10.1007\/s10388-026-01243-x","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"5 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is approved by the University of Osaka Hospital Ethical Review Board.","order":1,"name":"Ethics","label":"Ethical statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}